Mechanisms of MHC class I-restricted antigen presentation

By Hofmann Matthias   Nussbaum Alexander K   Emmerich Niels PN   Stoltze Lars   Schild Hansjörg  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 3, 2001-06 ,pp. : 379-393

Informa Healthcare

Access to resources Recommend Favorite

Anticancer Prodrugs for Application in Monotherapy Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors

By  

Current Medicinal Chemistry, Vol. 8, Iss. 9, 2001-07 ,pp. : 1093-1122

Bentham Science Publishers

Access to resources Recommend Favorite

MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 4, 2009-01 ,pp. : 344-352

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of T Cell Tolerance and Suppression in Cancer Mediated by Tumor-Associated Antigens and Hormones

By  

Current Cancer Drug Targets, Vol. 7, Iss. 1, 2007-02 ,pp. : 3-14

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the mTOR Pathway in Tumor Malignancy

By  

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 267-277

Bentham Science Publishers

Access to resources Recommend Favorite